The pace of recent developments in molecular biology has been unparalleled in modem medical history. Therapeutic manipulation of gene expression, considered to be in the realms of science fiction little more than a decade ago, is now being evaluated in clinical trials as a treatment for the genetic disorders that cause inborn errors of metabolism. The same technology is allowing investigators to consider the possibility of genetic manipulation, or gene therapy, as a treatment for acquired disorders, including atherosclerotic arterial disease, dilated cardiomyopathies, and restenosis after percutaneous vascular interventions. Two distinct approaches have been used as methods of influencing the molecular machinery of differentiated somatic cells. The first approach is gene therapy, which involves the introduction into cells of DNA encoding the production of a specific protein that has a local, regional, or systemic effect depending on whether it is retained within the cell or is actively secreted into the extracellular space. This approach may be used to replace proteins that are absent or defective owing to an inherited genetic abnormality or a spontaneous mutation, or to express therapeutic proteins with stimulatory or inhibitory activity as a treatment for acquired disorders.
The second molecular approach to cardiovascular therapeutics is the use of synthetic antisense oligonucleotides targeted to specific nuclear mRNA sequences. Oligonucleotides that are complementary, or antisense, to individual mRNA sequences bind to the sequence and prevent its translation. Inhibition of several cellular proto-oncogenes, including c-myb, c-myc, nonmuscle myosin, and proliferating cell nuclear antigen (PCNA) has been shown to inhibit smooth muscle cell proliferation in vitro.' Antisense oligonucleotides to c-myb have been successfully used to inhibit neointimal thickening in vivo in a balloon injured rat carotid artery model of restenosis.2 Although this approach has generated a great deal of interest and discussion, its clinical applicability remains limited by a relative lack of specificity,3 slow uptake across the cell membrane, and rapid intracellular degradation of the oligonucleotides.' The use of antisense technology as a potential treatment for the prevention of restenosis has been reviewed elsewhere.' The present editorial focuses on somatic gene therapy. that were isolated from a surgically resected segment of the patient's liver. 5 The treated cells were then reintroduced into the liver by infusion into the portal vein through a catheter left in situ at the time of the hepatic resection. In the first patient treated, the procedure was associated with a rapid and sustained reduction in serum LDL, an increase in serum in clinical practice. These considerations range from relatively minor technical concerns to far more difficult issues. Of greatest immediate concern for investigators treating patients with inherited single gene defects, in whom lifelong gene expression is desirable, are the questions of the efficiency of gene transfer and expression, the duration of gene expression, and the potential for mutagenesis and immunogenicity with repeated administration of the foreign gene and its vector. In the longer term the desire to obviate the need for tissue resection and ex vivo gene transfer will lead to the evaluation of intravenous gene delivery and the requirement for cell targeting and specificity of gene uptake and expression, for example by receptor-mediated DNA transfer'0 and through the use of cell-specific promoters.
Investigators interested in the treatment of acquired diseases have the added and substantial challenge of identifying therapeutic genes that are effective not only in the controlled environment of in vitro systems but also in diseased tissues in vivo. Secondly, while ex vivo gene transfer may continue to be feasible for certain conditions such as the prevention of arterial vein graft disease," direct gene transfer to specific sites in the arterial tree will require modification of previously used techniques.
Delivery systems used in peripheral arteries"5 may not be useful for coronary arterial gene transfer because of the need to avoid myocardial ischaemia during balloon inflation and the inability to control runoff into the large coronary side branches. Studies addressing these issues through the use of hydrogel-coated or microporous balloon catheters, implantable intravascular devices, and retrograde delivery from the coronary sinus are currently underway. More difficult issues that must also be addressed include the need for in vivo regulation of the transgene,'2 how to overcome constraints on the size of the gene that can be delivered, and how to rationalise the risk and cost benefits of this technically demanding treatment. Despite these limitations, however, there is every reason to be optimistic that gene therapy will not only be a first line treatment for certain inherited diseases, but may also become an invaluable adjunct or alternative to conventional mechanical and pharmacological treatments for acquired cardiovascular diseases. Complementary DNA (cDNA)-The DNA that has been copied from mRNA in a reaction catalysed by the enzyme reverse transcriptase.
Episomes-Genetic elements that can exist in stable form as pieces of nuclear DNA separate from the chromosomes.
Eukaryotic-Cells or organisms that contain a nucleus and that divide by mitosis (for example, yeast and mammalian cells).
Expression-Production of either a specific RNA or a peptide, depending on the context in which it is discussed.
Expression vector-A vector containing an inserted gene that is capable of inducing the synthesis of a large amount of protein coded by the gene when introduced into an appropriate host cell.
Gene-a sequence of DNA that carries the information encoding a polypeptide. It is the biological unit of heredity and is located at a defined locus on a particular chromosome.
Genome-The complete set of hereditary information in a species. It is composed of all the genes contained in the chromosomes.
Germ cells-Sperm and egg cells or their precursors. Foreign genes introduced into germ cells are passed on to the cells of the treated patient's progeny.
Hybridisation-The process of annealing two single strands of complementary nucleic acid to each other in order to form a double strand. Usually, one strand is a target sequence and the other is a labelled probe sequence.
In situ hybridisation-A procedure in which nucleic acid (DNA or RNA) of cells or tissue sections is denatured in situ so that reaction is possible with an added DNA or RNA probe. The added probe is labelled either radioactively or by an enzyme or protein marker and its hybridisation is detected by autoradiography, histochemistry, or immunohistochemistry.
Liposome-A synthetic vesicle consisting of a membrane of phospholipids used to facilitate transfection of DNA (or other macromolecules) into cells. Retrovirus-An RNA virus that propagates via conversion into DNA using the enzyme reverse transcriptase.
Reverse transcriptase-An enzyme found in retroviruses that can catalyse the synthesis of cDNA from mRNA.
Somatic cells-Cells other than sperm cells and egg cells. Gene transfer to these cells does not affect the offspring of the individual treated.
Transcription-The process of synthesising RNA on a DNA template.
Transfection-The transfer of new genetic material to a cell by the introduction of DNA.
Translation-The process of synthesising protein on an RNA template.
Vector-A molecule capable of autonomous replication, usually a bacteriophage or plasmid, that can grow in a particular host. It is used to receive, replicate, and allow the selection of the genomic DNA or cDNA of interest after introduction into the host. 
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